Biologic Sterile Injectable Outsourcing Volume

In Q2 2021, ISR asked 64 respondents how many biologic products they have on the market, the proportion of sterile injectable manufacturing that is outsourced and the number of CDMOs they use to complete the work. On average, respondents have 4.5 marketed biologic products, of which 65% of drug product manufacturing is outsourced and use an average of 3.3 CDMOs.  To learn how these proportions are predicted to change in the next five years, follow the link to the Sterile Injectable Market Outlook report preview.